Iovance Sparks More Optimism About Lifileucel’s Commercial Potential With New Analysis

 
• By Alaric DeArment

The company is presenting an updated Phase II analysis at SITC as it prepares to complete its rolling BLA submission and readies its commercial launch.

Iovance presented updated data from its Phase II study of lifileucel at SITC • Source: Shutterstock

More from Immuno-oncology

More from Anticancer